Bernstein Maintains Market Perform on Intellia Therapeutics, Raises Price Target to $17

Benzinga Newsdesk www.benzinga.com Positive 84.1%

Neg 0% Neu 0% Pos 84.1%

Bernstein analyst William Pickering maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Perform and raises the price target from $13 to $17.